Log In
Print this Print this

Labetuzumab govitecan (IMMU-130)

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionAntibody against carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5; CD66e) conjugated with SN-38, the active metabolite of irinotecan
Molecular Target Carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5) (CD66e)
Mechanism of ActionAntibody-drug conjugate; Binds CEA
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase II
Standard IndicationColorectal cancer
Indication DetailsTreat metastatic colorectal cancer (mCRC) in patients previously treated with >=1 prior irinotecan-containing regimen; Treat relapsed or refractory colorectal cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today